Modulation of the Immune Response by Deferasirox in Myelodysplastic Syndrome Patients

Modulation of the Immune Response by Deferasirox in Myelodysplastic Syndrome Patients

Deferasirox (DFX) is an oral iron chelator used to reduce iron overload (IO) caused by frequent blood cell transfusions in anemic myelodysplastic syndrome (MDS) patients. To study the molecular mechanisms by which DFX improves outcome in MDS, we analyzed the global gene expression in untreated MDS p...

Full description

Bibliographic Details
Main Authors: Hana Votavova, Zuzana Urbanova, David Kundrat, Michaela Dostalova Merkerova, Martin Vostry, Monika Hruba, Jaroslav Cermak, Monika Belickova
Format: Article
Language:English
Published: MDPI AG 2021-01-01
Series:Pharmaceuticals
Subjects:
myelodysplastic syndrome
iron chelation
deferasirox
molecular mechanisms
Online Access:https://www.mdpi.com/1424-8247/14/1/41

Internet

https://www.mdpi.com/1424-8247/14/1/41

Similar Items